Targeted Oncology

Risk-Based First-Line Selection in Advanced Renal Cell Carcinoma

In this segment focused on advanced renal cell carcinoma, Dr. Geynisman shifts the discussion to patients with intermediate ...
The American Journal of Managed Care

IO-TKI Combinations Have Potential as Preferred First-line mRCC Therapy

Metastatic renal cell carcinoma (mRCC) has seen increased treatment options in recent years, including immunotherapy (IO) combinations paired with tyrosine kinase inhibitors (TKI). A meta-analysis of ...
ascopubs.org

Metastatic renal cell carcinoma (mRCC) primary refractory patients to first-line IO-TKI and IO-IO combinations (Meet-URO 33 analysis).

Comparing the effectiveness of IO-based combination regimens as first-line treatment for advanced clear-cell renal cell carcinoma (ccRCC). This is an ASCO Meeting Abstract from the 2025 ASCO ...
MedPage Today

In BRAF-Mutant Melanoma, a Real-World Look at Systemic Therapy Sequencing

There is little available guidance in the selection of IO or TT in the first-line setting for patients with advanced cutaneous melanoma. No significant difference was detected between the use of first ...
ascopubs.org

Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors—Data From the ARON-1 Study

First-line IO-based combinations provide clinically meaningful survival in sRCC, with outcomes affected by sex, metastatic sites, and IMDC risk. This RWE may support a tailored therapeutic approach on ...